Short Interest in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Rises By 68.1%

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNTGet Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 47,900 shares, a growth of 68.1% from the March 31st total of 28,500 shares. Based on an average daily volume of 63,200 shares, the days-to-cover ratio is currently 0.8 days.

A number of hedge funds and other institutional investors have recently bought and sold shares of OPNT. Two Sigma Advisers LP acquired a new position in Opiant Pharmaceuticals during the third quarter valued at $2,139,000. EAM Investors LLC acquired a new position in Opiant Pharmaceuticals during the third quarter valued at $1,777,000. Two Sigma Investments LP acquired a new position in Opiant Pharmaceuticals during the third quarter valued at $1,314,000. Geode Capital Management LLC lifted its position in Opiant Pharmaceuticals by 290.0% during the third quarter. Geode Capital Management LLC now owns 50,244 shares of the technology company’s stock valued at $1,293,000 after purchasing an additional 37,362 shares during the period. Finally, DLD Asset Management LP acquired a new position in Opiant Pharmaceuticals during the fourth quarter valued at $1,009,000. Institutional investors own 26.48% of the company’s stock.

Several equities analysts have issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Opiant Pharmaceuticals in a report on Wednesday, March 16th. TheStreet downgraded shares of Opiant Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Monday, April 18th.

NASDAQ:OPNT opened at $19.96 on Friday. Opiant Pharmaceuticals has a 12 month low of $11.55 and a 12 month high of $37.71. The firm has a fifty day simple moving average of $23.15 and a 200-day simple moving average of $26.40. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $101.40 million, a P/E ratio of 62.38 and a beta of 0.61.

Opiant Pharmaceuticals (NASDAQ:OPNTGet Rating) last posted its quarterly earnings data on Tuesday, March 15th. The technology company reported $0.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.12. Opiant Pharmaceuticals had a net margin of 6.40% and a return on equity of 7.69%. During the same quarter in the prior year, the company earned ($0.16) earnings per share. Equities analysts forecast that Opiant Pharmaceuticals will post -4.42 EPS for the current year.

About Opiant Pharmaceuticals (Get Rating)

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders.

See Also

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.